Author:
Nakajima Keitaro,Dagher Ramzi,Strawn Laurie,Urushidani Jun,Kurokawa Tatsuo,Chiba Koji
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference16 articles.
1. Yonemori K, Hirakawa A, Ando M, et al. The notorious “drug lag” for oncology drugs in Japan. Invest New Drugs. 2011;29(4):706–712.
2. Hashimto J, Ueda E, Narukawa M. The current situation of oncology drug lag in Japan and strategic approaches for pharmaceutical companies. Drug Inf J. 2009;43:757–765.
3. Kawabata-Shoda E, Masuda S, Kimura H. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan. J Clin Pharm Ther. 2012;37(5):547–552.
4. Haseto S, Ono S. Research paper: Volume 55. Tokyo, Japan: Office of Pharmaceutical Industry Research; 2012.
5. Pharmaceuticals and Medical Devices Agency. Outline of PMDA’s second midterm plan and goal. http://www.pmda.go.jp/guide/hyougikai/20/h210316gijishidai/file/h210316shiryo1-3.pdf. Published 2009. Accessed December 22, 2013.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献